Paxlovid treatment in 20% of COVID-19 patients could avert 850,000 hospitalizations, save up to $170 billion

A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce the economic burden by US $170.17 billion in the US.

Related Keywords

United States ,American ,America ,Dmitriy Prayzel ,National Household Travel ,Drug Administration ,Public Health Impact Of Paxlovid As Treatment ,Emerging Infectious Diseases ,Stated States ,Public Health Impact ,Image Credit ,Emergency Use Authorization ,National Household Travel Survey ,Coronavirus Disease Covid 19 ,Antiviral Drug ,Clinical Trial ,Coronavirus ,Drugs ,Efficacy ,Mmunodeficiency ,Infectious Diseases ,Pandemic ,Public Health ,Reproduction ,Espiratory ,Na ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,Virus ,